drugset / Trial / NCT00530764

A Study of Sativex® for Pain Relief in Patients With Advanced Malignancy.

NCT00530764

Phase 2 Completed 360 enrolled GW Pharmaceuticals Ltd Quintiles, Inc. · collab
RandomizedParallel-groupQuadruple-blindSupportive care

Summary

The purpose of this study is to determine the effective dose range and to demonstrate a non-effective dose range of Sativex in patients with advanced cancer, who experience inadequate pain relief even though they are on optimized chronic opioid therapy.

Timeline

Start
2007-11
Primary completion
2010-01
Completion
2010-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Nabiximols Other / unclassified Other

Indications